The lancet oncology
-
The lancet oncology · Mar 2008
Randomized Controlled Trial Multicenter StudyS-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial.
Phase I/II clinical trials of S-1 plus cisplatin for advanced gastric cancer have yielded good responses and the treatment was well tolerated. In this S-1 Plus cisplatin versus S-1 In RCT In the Treatment for Stomach cancer (SPIRITS) trial, we aimed to verify that overall survival was better in patients with advanced gastric cancer treated with S-1 plus cisplatin than with S-1 alone. ⋯ S-1 plus cisplatin holds promise of becoming a standard first-line treatment for patients with advanced gastric cancer.